Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders

Mitochondrial disorders share common cellular consequences: (1) decreased ATP production; (2) increased reliance on alternative anaerobic energy sources; and (3) increased production of reactive oxygen species. The purpose of the present study was to determine the effect of a combination therapy (creatine monohydrate, coenzyme Q10, and lipoic acid to target the above‐mentioned cellular consequences) on several outcome variables using a randomized, double‐blind, placebo‐controlled, crossover study design in patients with mitochondrial cytopathies. Three patients had mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS), four had mitochondrial DNA deletions (three patients with chronic progressive external ophthalmoplegia and one with Kearns–Sayre syndrome), and nine had a variety of other mitochondrial diseases not falling into the two former groups. The combination therapy resulted in lower resting plasma lactate and urinary 8‐isoprostanes, as well as attenuation of the decline in peak ankle dorsiflexion strength in all patient groups, whereas higher fat‐free mass was observed only in the MELAS group. Together, these results suggest that combination therapies targeting multiple final common pathways of mitochondrial dysfunction favorably influence surrogate markers of cellular energy dysfunction. Future studies with larger sample sizes in relatively homogeneous groups will be required to determine whether such combination therapies influence function and quality of life. Muscle Nerve, 2006

[1]  T. Klockgether,et al.  Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo‐controlled, double‐blind 31P‐MRS crossover study , 2005, European journal of neurology.

[2]  N. Chu,et al.  Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. , 1997, European neurology.

[3]  A. Straube,et al.  A placebo-controlled crossover trial of creatine in mitochondrial diseases , 2000, Neurology.

[4]  L. Packer,et al.  Comparison of the effect of α-lipoic acid and α-tocopherol supplementation on measures of oxidative stress , 1999 .

[5]  A. Rötig [Mitochondrial cytopathies]. , 1996, Pathologie-biologie.

[6]  P. Brugières,et al.  Choreic movements and MRI abnormalities in the subthalamic nuclei reversible after administration of coenzyme Q10 and multiple vitamins in a patient with bilateral optic neuropathy , 1999, Movement disorders : official journal of the Movement Disorder Society.

[7]  I. MacDonald,et al.  Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. , 2004, Molecular genetics and metabolism.

[8]  M. Tarnopolsky,et al.  Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. , 2003, International journal of sport nutrition and exercise metabolism.

[9]  E Hultman,et al.  Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. , 1992, Clinical science.

[10]  A. Boneh,et al.  Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases , 2004, Journal of Inherited Metabolic Disease.

[11]  I. Nonaka,et al.  Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2 , 1997, Brain and Development.

[12]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[13]  M. Tarnopolsky,et al.  Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. , 2005, Medicine and science in sports and exercise.

[14]  M. Beal,et al.  A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2'-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. , 1999, Free radical biology & medicine.

[15]  N. Bresolin,et al.  Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial , 1990, Journal of the Neurological Sciences.

[16]  M. Tarnopolsky,et al.  A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies , 1997, Muscle & nerve.

[17]  P. Peterson,et al.  The treatment of mitochondrial myopathies and encephalomyopathies. , 1995, Biochimica et biophysica acta.

[18]  F. Hanefeld,et al.  Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. , 2003, Pediatric neurology.

[19]  J. Haines,et al.  Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation. , 2005, Free radical biology & medicine.

[20]  M. Tarnopolsky,et al.  Direct measurement of high‐energy phosphate compounds in patients with neuromuscular disease , 1999, Muscle & nerve.

[21]  M. Tarnopolsky,et al.  Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy , 2004, Neurology.

[22]  M. Tarnopolsky,et al.  Nutritional and exercise-based therapies in the treatment of mitochondrial disease , 2002, Current opinion in clinical nutrition and metabolic care.

[23]  Gianni Parise,et al.  Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[24]  M. Widlansky,et al.  Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. , 2004, Current medicinal chemistry.

[25]  G. Siciliano,et al.  Long-term treatment with idebenone and riboflavin in a patient with MELAS , 2000, Neurological Sciences.

[26]  P. Matthews,et al.  Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease , 1993, Neurology.

[27]  R. Artuch,et al.  Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease , 1998, Journal of Inherited Metabolic Disease.

[28]  P. Montuschi,et al.  Isoprostanes: markers and mediators of oxidative stress , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  P. Bénit,et al.  Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. , 2002, Molecular genetics and metabolism.

[30]  D. Glerum,et al.  Nutritional cofactor treatment in mitochondrial disorders. , 2003, Journal of the American Dietetic Association.

[31]  M. Beal,et al.  Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders , 2001, Annals of neurology.

[32]  P. Sestili,et al.  Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. , 2006, Free radical biology & medicine.

[33]  M. Tarnopolsky,et al.  Creatine monohydrate increases strength in patients with neuromuscular disease , 1999, Neurology.

[34]  J. Morrow,et al.  F2-Isoprostanes as markers of oxidative stress in vivo: An overview , 2005, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[35]  A. M. Salio,et al.  Coenzyme Q 10 Improves Lactic Acidosis, Strokelike Episodes, and Epilepsy in a Patient With MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Strokelike episodes) , 2004, Clinical neuropharmacology.

[36]  Yau-Huei Wei,et al.  Increased 8-hydroxy-2'-deoxyguanosine in leukocyte DNA in Leber's hereditary optic neuropathy. , 2004, Investigative ophthalmology & visual science.

[37]  L. Migliore,et al.  Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. , 2004, Mutagenesis.

[38]  J. Lawler,et al.  Direct antioxidant properties of creatine. , 2002, Biochemical and biophysical research communications.

[39]  M. Tarnopolsky,et al.  Patients with dystrophinopathy show evidence of increased oxidative stress. , 2003, Free radical biology & medicine.